ANGIODYNAMICS INC Q3 FY2025 earnings call

• MedTech segment: Auryon launched AMBITION BTK trial, Mechanical Thrombectomy products (AlphaVac and AngioVac) showed strong synergies, NanoKnife had prostate indication and positive clinical data. - Med Device segment: Return to growth, improved adjusted EBITDA, and focus on profitability. - Clinical and regulatory: Launched AMBITION BTK trial, publication of APEX-AV trial results highlighting safety/efficacy of AlphaVac F1885 System for PE.

MedTech segment: Revenue was $31.3 million, growing 22.2%, making up 44% of total revenue. Auryon contributed $13.9 million, up 17.3%. Mechanical Thrombectomy (AlphaVac and AngioVac) grew 46.7% year-over-year, with AlphaVac at $3 million (up 161.4%) and AngioVac at $6.8 million (up 23.1%). NanoKnife revenue was $6.3 million, up 5.3%. Med Device segment: Revenue was $40.7 million, up 1%, with adjusted EBITDA of $1.3 million in Q3 2025 compared to a loss of $3.6 million in Q3 2024.

• Fiscal 2025 revenue expected $285-288 million (5.3%-6.4% growth). - MedTech net sales growth 14%-16%, up from previous guidance. - Gross margin 53%-54%, up from 52%-53%. - Adjusted EBITDA $4-5 million, up from $1-3 million. - Adjusted loss per share $0.31-0.34, improved from previous guidance.

• Macro environment and potential tariffs, though currently not expected to materially impact the business as most products are manufactured in the U.S. with U.S.-based suppliers.

Q: John Young asked about AngioVac's future base and NanoKnife prostate details.

A: Stephen Trowbridge said AngioVac is a growth platform, Jim Clemmer discussed NanoKnife's education campaigns and increasing prostate cases.

Q: Steven Lichtman inquired about Mechanical Thrombectomy commercial efforts and Auryon EU launch.

A: Jim Clemmer talked about expanding the thrombectomy sales force and ongoing EU education, Stephen Trowbridge noted international market not material yet.

Q: Eduardo Martinez asked about AMBITION study and Auryon marketing.

A: Stephen Trowbridge explained the AMBITION study's rationale and that Auryon's commercial team would be sufficient with opportunistic investment.